Astrazeneca Ab

Eva-Lotte Alstermark Lindstedt

Lanna Li

Anna Christina Olsson

Patrick Holm

Anna Maria Persdotter Boije

The present invention provides the S enantiomer of a compound of formula (I) wherein n is 1 or 2 as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor &#x3b1; (PPAR)

A compound of formula I wherein Rrepresents chloro, fluoro or hydroxy as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, processes for preparing such compounds, their utility in treating clinical conditions associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha

The present invention provides the S enantiomer of a compound of formula (I); wherein Rrepresents 2,4-difluorophenyl or cyclohexyl as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Growing community of inventors

Molndal, Sweden

Eva-Lotte Alstermark Lindstedt